TLDR A patient developed hair loss after hepatitis C treatment with sofosbuvir and ribavirin.
A case report from April 2021 described a rare instance of alopecia areata developing in a patient following treatment with the interferon-free direct-acting antiviral (DAA) therapy combination of sofosbuvir and ribavirin (SOF/RBV) for chronic hepatitis C virus (HCV) infection. Despite the generally low side effects associated with DAA therapies, this case highlighted alopecia areata as a potential, though uncommon, complication.
34 citations
,
April 2008 in “Journal of the European Academy of Dermatology and Venereology” Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.
41 citations
,
August 2007 in “European Journal of Gastroenterology & Hepatology” A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.
27 citations
,
April 2005 in “Journal of Chemotherapy” Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
9 citations
,
May 2005 in “Expert Review of Clinical Immunology” Blocking interferon-gamma might help treat various autoimmune diseases.
January 2024 in “Frontiers in immunology” Histone modification is key in treating chronic inflammatory skin diseases.
3 citations
,
May 2023 in “Frontiers in immunology” Faulty inflammasome activation may lead to autoimmune skin diseases and could be a target for new treatments.
January 2025 in “International Journal of Molecular Sciences” Psoriasis involves immune and genetic factors, and understanding these can improve treatments.
3 citations
,
June 2023 in “Molecules/Molecules online/Molecules annual” Cepharanthine has many medicinal uses but needs improvement for better effectiveness.
